Krems an der Donau, Austria, 16 November 2012 – Lacerta Technologies GmbH has been successfully established in Krems an der Donau/Lower Austria in close proximity to the local Danube University as important R&D co-operation partner. The company has been founded by Dr. Zsom-bor Lacza (CEO) and Björn Ehring (CFO) as angel investor. Lacerta Technologies initially focuses on the commercialization of innovative bone grafting technologies which have been developed by Dr. Lacza’s research group at Semmelweis University in Budapest/Hungary.
The establishment of the entity followed the successful application for seed funding from the national government agency Austria Wirtschaftsservice and accent Gründer-service based in Lower Austria.
Profile Lacerta Technologies GmbH
Founded in 2012 and located in Krems an der Donau/Austria Lacerta Technologies GmbH is a development-stage regenerative medicine company aiming to translate research results into products for routine clinical use. We put special emphasis on designing simple and affordable protocols allowing a wider patient population to benefit from cell therapy.
Our current development projects include an innovative albumin-coated bone allograft and a point-of-care device for the personalized production of autologous bone grafts.
Lacerta Technologies GmbH Dr.-Karl-Dorrek-Straße 23-29
A-3500 Krems an der Donau
Tel/Fax: +43 664 77 883 16206